Desensitization using IVIG alone for living-donor kidney transplant: impact on donor-specific antibodies

Autor: Luiz Roberto de Sousa Ulisses, Jenaine Oliveira Paixão, Fabiana Agena, Patrícia Soares de Souza, Flávio J Paula, Gislene Bezerra, Hélcio Rodrigues, Nicolas Panajotopolous, Elias David-Neto, Maria Cristina Ribeiro de Castro
Jazyk: English<br />Portuguese
Rok vydání: 2022
Předmět:
Zdroj: Brazilian Journal of Nephrology (2022)
Druh dokumentu: article
ISSN: 2175-8239
DOI: 10.1590/2175-8239-jbn-2021-0200
Popis: Abstract Introduction: Sensitization to human leukocyte antigen is a barrier to. Few data have been published on desensitization using polyvalent human intravenous immunoglobulin (IVIG) alone. Methods: We retrospectively reviewed the of 45 patients with a positive complement-dependent cytotoxicity crossmatch (CDCXM) or flow cytometry crossmatch (FCXM) against living donors from January 2003 to December 2014. Of these, 12 were excluded. Patients received monthly IVIG infusions (2 g/kg) only until they had a negative T-cell and B-cell FCXM. Results: During the 33 patients, 22 (66.7%) underwent living donor kidney transplantation, 7 (21.2%) received a deceased donor graft, and 4 (12.1%) did not undergo transplantation. The median class I and II panel reactive antibodies for these patients were 80.5% (range 61%-95%) and 83.0% (range 42%-94%), respectively. Patients (81.8%) had a positive T-cell and/or B-cell CDCXM and 4 (18.2%) had a positive T-cell and/or B-cell FCXM. Patients underwent transplantation after a median of 6 (range 3-16). The median donor-specific antibody mean fluorescence intensity sum was 5057 (range 2246-11,691) before and 1389 (range 934-2492) after desensitization (p = 0.0001). Mean patient follow-up time after transplantation was 60.5 (SD, 36.8) months. Nine patients (45.0%). Death-censored graft survival at 1, 3, and 5 years after transplant was 86.4, 86.4, and 79.2%, respectively and patient survival was 95.5, 95.5, and 83.7%, respectively. Conclusions: Desensitization using IVIG alone is an effective strategy, allowing successful transplantation in 87.9% of these highly sensitized patients.
Databáze: Directory of Open Access Journals